# High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC

> **NCT07182708** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 62 (estimated)

## Conditions studied

- NSCLC (Non-small Cell Lung Cancer)
- EGFR Activating Mutation
- Resectable Lung Non-Small Cell Carcinoma

## Interventions

- **DRUG:** Firmonertinib Mesilate Tablets
- **DRUG:** Bevacizumab injection

## Key facts

- **NCT ID:** NCT07182708
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2029-12-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07182708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07182708, "High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07182708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*